The fight over rural healthcare in 2026 will be framed as a partisan battle, but the forces actually squeezing hospitals that serve small towns are corporate drugmakers and their lobbyists. This piece explains how the 340B discount program works, why a handful of pricey cancer and HIV medicines are driving costs, and how industry lobbying priorities and past behavior reveal who benefits from weakening the program that keeps rural clinics alive.
New data show ten drugs made up 28.6 percent of the roughly $100 billion spent through the 340B program in 2025, a jump of about 23 percent from the prior year. Four of those ten are oncology drugs and two treat HIV, with Merck’s Keytruda alone representing $8.9 billion in 340B purchases. Those numbers matter because they point to where list prices have surged fastest and where rural patients have the least capacity to absorb higher costs.
The 340B program requires drug manufacturers that participate in federal programs to offer outpatient medicines at a discount to safety-net hospitals and rural clinics. Hospitals then use the resulting savings to keep clinics open and to provide care, including cancer therapy and HIV treatment, for patients who otherwise would not get those medications. The program does not come with a taxpayer bill for the discounts; instead it preserves access in communities that might otherwise lose services.
Pharmaceutical makers who dominate the top-spending list are members of the industry’s main lobbying group, which has been pushing policy changes aimed at cutting what hospitals can keep from 340B savings. Those proposals focus on rebates, reporting mandates, and payment shifts that would move costs onto hospitals rather than forcing companies to address soaring list prices. It is valid to challenge abuses, but proposed industry fixes tend to avoid the central problem: list prices that keep climbing for lifesaving drugs.
History matters here. Companies with problematic pasts have long been part of the industry coalition arguing for rollback of safety-net protections. Some members once defended aggressive marketing practices and only distanced themselves after legal or financial pressure mounted. Meanwhile, the hospitals using 340B savings fund addiction treatment, mental health services, and other vital programs in regions hit hard by opioid and other public health crises. There is a striking disconnect between industry rhetoric and the practical role 340B plays on the ground.
Policy moves under the prior administration aimed to make enforcement of 340B rules more effective by setting a ceiling price and giving regulators authority to sanction overcharging. That enforcement has led to actions against manufacturers found to have shorted hospitals, showing the rule can have teeth when used. At the same time, industry lobbying has repeatedly sought delay or dilution of enforcement, exposing a preference for protecting revenue over preserving access for vulnerable communities.
The debate about how hospitals use their 340B margins is not trivial. Large systems have sometimes used savings in ways that raise legitimate questions about mission alignment, and critics deserve a clear accounting. But reforms that simply divert money from hospitals to manufacturers do not lower list prices or address the underlying drivers of drug inflation. If the goal is to keep rural clinics open, policy must target price, not just the distribution of program revenue.
Beyond the specifics of 340B, the broader pattern is consistent: an industry that treats discounts to safety-net providers as a line item to be optimized will resist reforms that threaten profit. That resistance shows up across multiple issue areas, from childhood healthcare debates to vaccine policy fights. When lobbying power meets concentrated price increases in oncology and HIV drugs, the consequences fall hardest on patients with the fewest alternatives.
When trade groups and manufacturers argue that 340B is the core problem for rural hospitals, it helps to remember who benefits most from the program and who stands to gain from its weakening. The ten medicines consuming a large share of program spending are largely cancer and HIV treatments—categories where price spikes hit patients and small providers the hardest. Any policy conversation that ignores that fact risks worsening access for the communities 340B was designed to protect.
Add comment